Cardiovascular mortality · CVD (ASCVD, HF, or both)
GLP‐1RA leads to lower cardiovascular mortality compared with placebo (high certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · CVD (ASCVD, HF, or both)
GLP‐1RA showed no clear difference in myocardial infarction (fatal or non‐fatal) compared with placebo (moderate certainty).
1 finding from 1 review
Fatal or nonfatal stroke · CVD (ASCVD, HF, or both)
GLP‐1RA leads to lower stroke (fatal or non‐fatal) compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality · CVD (ASCVD, HF, or both)
GLP‐1RA leads to lower all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · CVD (ASCVD, HF, or both)
GLP‐1RA showed no clear difference in hospitalisation for HF compared with placebo (high certainty).
1 finding from 1 review
Worsening kidney function · CVD (ASCVD, HF, or both)
GLP‐1RA may leads to lower worsening renal function compared with placebo (low certainty).
1 finding from 1 review
Hypoglycaemia · CVD (ASCVD, HF, or both)
1 finding from 1 review
Pancreatitis · CVD (ASCVD, HF, or both)
GLP‐1RA showed no clear difference in pancreatitis compared with placebo (low certainty).
1 finding from 1 review
Fracture · CVD (ASCVD, HF, or both)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found